Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.
Also called NCT06202378
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 270 participants
- Registry
-
NCT06202378
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06202378. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-29 (actual); primary completion 2024-11-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- 3 ampoules of SHPL-49 Injection
- Intervention (Drug)
- 6 ampoules of SHPL-49 Injection
- Intervention (Drug)
- 0.9% Sodium Chloride Injection
- Lead sponsor
- Shanghai Hutchison Pharmaceuticals Limited
- Collaborator
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct06202378- Content hash
f11806900905de9602302e573152c7e7666c6d96966a11fd7bee534c452dfc5a